These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8059802)

  • 1. Reducing costs and hospital stay for pneumonia with home intravenous cefotaxime treatment: results with a computerized ambulatory drug delivery system.
    Williams DN
    Am J Med; 1994 Aug; 97(2A):50-5. PubMed ID: 8059802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients.
    Morales JO; Snead H
    Am J Med; 1994 Aug; 97(2A):28-33. PubMed ID: 8059798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient antibiotic therapy for elderly patients. HIAT Study Group.
    Angel JV
    Am J Med; 1994 Aug; 97(2A):43-9. PubMed ID: 8059801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary bacterial infections in HIV-infected patients: an alternative ambulatory outpatient treatment utilizing intravenous cefotaxime.
    Morales JO; Von Behren L
    Am J Med; 1994 Aug; 97(2A):9-13. PubMed ID: 8059803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug delivery device: a multicenter trial. HIAT Study Group.
    Poretz DM
    Am J Med; 1994 Aug; 97(2A):23-7. PubMed ID: 8059797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of serious infections with cefotaxime utilizing an outpatient drug delivery device: global analysis of a large-scale, multicenter trial. HIAT Study Group.
    Poretz DM
    Am J Med; 1994 Aug; 97(2A):34-42. PubMed ID: 8059800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program.
    Williams DN; Bosch D; Boots J; Schneider J
    Clin Ther; 1993; 15(1):169-79; discussion 168. PubMed ID: 8458046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of bone and joint infections utilizing a third-generation cephalosporin with an outpatient drug delivery device. HIAT Study Group.
    Mauceri AA
    Am J Med; 1994 Aug; 97(2A):14-22. PubMed ID: 8059796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of twice-daily cefotaxime compared to conventional therapy for the treatment of infections in a USA hospital.
    Burke JP; Pestotnik SL; Classen DC; Lloyd JF
    Diagn Microbiol Infect Dis; 1995; 22(1-2):167-9. PubMed ID: 7587034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambulatory antibiotic infusion devices: extending the spectrum of outpatient therapies.
    New PB; Swanson GF; Bulich RG; Taplin GC
    Am J Med; 1991 Nov; 91(5):455-61. PubMed ID: 1951407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home intravenous antibiotic therapy using a programmable infusion pump.
    Williams DN; Gibson JA; Bosch D
    Arch Intern Med; 1989 May; 149(5):1157-60. PubMed ID: 2719507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
    Zhou QT; He B; Zhu H
    Value Health; 2009; 12(1):40-6. PubMed ID: 18637052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital-in-the-home treatment of surgical infectious diseases: an economic analysis.
    Mazo S; Emparan C; Vallejo M; Soriano P
    Surg Infect (Larchmt); 2007 Dec; 8(6):567-74. PubMed ID: 18171115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia.
    Fine MJ; Pratt HM; Obrosky DS; Lave JR; McIntosh LJ; Singer DE; Coley CM; Kapoor WN
    Am J Med; 2000 Oct; 109(5):378-85. PubMed ID: 11020394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient time-specified infusion of fluoropyrimidines by implanted pump is less costly than flat delivery by external pump.
    Lanning RM; Hrushesky WJ
    Prog Clin Biol Res; 1990; 341B():397-409. PubMed ID: 2145587
    [No Abstract]   [Full Text] [Related]  

  • 17. Cefotaxime and ceftriaxone use evaluation in pediatrics. Considerations of cost effectiveness.
    Lee CK; Glenn DJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):231-3. PubMed ID: 7587045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiologic and economic evaluation of multiday infusion pumps for control of cancer pain.
    Ohlsson LJ; Rydberg TS; Edén T; Glimhall BA; Thulin LA
    Ann Pharmacother; 1995 Oct; 29(10):972-6. PubMed ID: 8845556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins.
    Tice AD
    Drugs; 2000; 59 Suppl 3():29-35; discussion 47-9. PubMed ID: 10845411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.